The potential value of Clostridium difficile vaccine: An economic computer simulation model

Bruce Y. Lee; Michael J. Popovich; Ye Tian; Rachel R. Bailey; Paul J. Ufberg; Ann E. Wiringa; Robert R. Muder

doi:10.1016/j.vaccine.2010.05.062

The potential value of Clostridium difficile vaccine: An economic computer simulation model

Bruce Y. Lee, Michael J. Popovich, Ye Tian, Rachel R. Bailey, Paul J. Ufberg, Ann E. Wiringa, Robert R. Muder

Research output: Contribution to journal › Article › peer-review

Abstract

Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.

Original language	English (US)
Pages (from-to)	5245-5253
Number of pages	9
Journal	Vaccine
Volume	28
Issue number	32
DOIs	https://doi.org/10.1016/j.vaccine.2010.05.062
State	Published - Jul 2010
Externally published	Yes

Keywords

Clostridium difficile
Computer simulation
Economics
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.05.062

Fingerprint Dive into the research topics of 'The potential value of Clostridium difficile vaccine: An economic computer simulation model'. Together they form a unique fingerprint.

Cite this

@article{8a7f1b31c8ee4073977e22711cd18c2e,

title = "The potential value of Clostridium difficile vaccine: An economic computer simulation model",

abstract = "Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.",

keywords = "Clostridium difficile, Computer simulation, Economics, Vaccine",

author = "Lee, {Bruce Y.} and Popovich, {Michael J.} and Ye Tian and Bailey, {Rachel R.} and Ufberg, {Paul J.} and Wiringa, {Ann E.} and Muder, {Robert R.}",

note = "Funding Information: This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) grant 1U54GM088491-0109 , the Pennsylvania Department of Health, and the Vaccine Modeling Initiative (VMI), funded by the Bill and Melinda Gates Foundation . The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "2010",

month = jul,

doi = "10.1016/j.vaccine.2010.05.062",

language = "English (US)",

volume = "28",

pages = "5245--5253",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "32",

}

TY - JOUR

T1 - The potential value of Clostridium difficile vaccine

T2 - An economic computer simulation model

AU - Lee, Bruce Y.

AU - Popovich, Michael J.

AU - Tian, Ye

AU - Bailey, Rachel R.

AU - Ufberg, Paul J.

AU - Wiringa, Ann E.

AU - Muder, Robert R.

N1 - Funding Information: This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) grant 1U54GM088491-0109 , the Pennsylvania Department of Health, and the Vaccine Modeling Initiative (VMI), funded by the Bill and Melinda Gates Foundation . The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 2010/7

Y1 - 2010/7

N2 - Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.

AB - Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.

KW - Clostridium difficile

KW - Computer simulation

KW - Economics

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77954953150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954953150&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.05.062

DO - 10.1016/j.vaccine.2010.05.062

M3 - Article

C2 - 20541582

AN - SCOPUS:77954953150

VL - 28

SP - 5245

EP - 5253

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -